CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 312 enrolled
Drug / intervention
Leuprorelin acetatedrug
Likely dose
Leuprorelin acetate 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03209518
NCT03209518N/ACompleted
CompareCT.gov

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

Takeda·observational·Posted Jul 6, 2017·Updated Nov 1, 2019

In Brief

An observational study evaluating Leuprorelin acetate for Premenopausal Breast Cancer. Completed, enrolled 312 participants across 1 site.

Detailed Summary

The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPremenopausal Breast Cancer
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 6, 2017
Enrollment StartMar 18, 2016
Primary CompletionOct 10, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.0 years ago

Interventions

Leuprorelin acetatedrug

Leuplin PRO for Injection Kit 22.5 mg